Bronchiectasis Exacerbation Management

A medical professional explores the management of bronchiectasis exacerbations, detailing the significance of sputum color, the potential for hemoptysis, and the exacerbation of comorbidities such as COPD and asthma.

EP: 1.Overview of Bronchiectasis

EP: 2.Prognosis For Patients Diagnosed With Bronchiectasis

EP: 3.Indicators Leading to Bronchiectasis Testing and Diagnosis

EP: 4.Complications Associated With Bronchiectasis

EP: 5.Current Treatment Options For Bronchiectasis

EP: 6.Respiratory and Physical Therapists Contributing to Comprehensive Bronchiectasis Care

EP: 7.Key Areas of Research and Emerging Therapies In Bronchiectasis Treatment

EP: 8.Diagnosing and Understanding the Pathogenesis of Bronchiectasis

EP: 9.Improving Long-Term Outlook: CT Scans and Underdiagnosis of Bronchiectasis

Now Viewing

EP: 10.Bronchiectasis Exacerbation Management

EP: 11.Social Burden and Goals of Therapy for Patients with Bronchiectasis

EP: 12.Patient Specific Factors: Guiding Treatment in Bronchiectasis

EP: 13.Individualized Therapy for Specific Infections Associated with Bronchiectasis

EP: 14.Other Challenges With Bronchiectasis and Key Takeaways

EP: 15.Identifying Bronchiectasis: Key Clinical Presentations to Consider

EP: 16.Differentiating Bronchiectasis from COPD and Understanding Exacerbations

EP: 17.Long-Term Impact of Bronchiectasis Exacerbations: Disease Progression, Patient Outcomes, and Economic Burden

EP: 18.Managing Bronchiectasis: Treatment Goals, Outcome Measures, and Clinical Decision Resources

EP: 19.Addressing Knowledge Gaps and Treatment Strategies in Bronchiectasis

EP: 20.Challenges and Future Directions in Bronchiectasis Management

Related Videos

Related Content

Advertisement

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

Brooke McCormick

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Related Content

Advertisement

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

Brooke McCormick

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.